Fiche société
Beeline Medicines Corporation
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications2liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AfimetoranThe purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran. | Lupus | Phase 2/3 | À vérifier | United States | À vérifier |
| AfimetoranThe purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran. | Lupus | Phase 2 | À vérifier | United States, Argentina, Australia, Brazil, Chile, China, Colombia, France, Germany, India, Ireland, Japan, Mexico, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom | À vérifier |
| AfimetoranThe purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran. | Lupus | Phase 2/3 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Afimetoran | Lupus | Phase 2/3 | NCT07881120 | DISCOVERY — Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus | RECRUITING |
| Afimetoran | Lupus | Phase 2 | NCT04895696 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Afimetoran | Structural and immunological impacts of TOLLIP nsSNPs: A computational biology approach to drug discovery and immune system modulation. | PloS one | ||
| Afimetoran | Development of Kilogram-Scale Electrochemical Ni-Catalyzed Cross Electrophile Coupling in Flow. | Organic process research & development |